Abstract
This cross-sectional study assesses the availability of the direct oral anticoagulant reversal agents idarucizumab and andexanet alfa in US hospitals.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have